Noramco LLC v. Dishman USA, Inc.

CourtDistrict Court, D. Delaware
DecidedJuly 19, 2022
Docket1:21-cv-01696
StatusUnknown

This text of Noramco LLC v. Dishman USA, Inc. (Noramco LLC v. Dishman USA, Inc.) is published on Counsel Stack Legal Research, covering District Court, D. Delaware primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Noramco LLC v. Dishman USA, Inc., (D. Del. 2022).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE

NORAMCO LLC, § §

Plaintiff, §

§

v. § Civil Action No. 21-1696-WCB §

DISHMAN USA, INC., §

§ Defendant. §

MEMORANDUM OPINION AND ORDER

Plaintiff Noramco LLC (“Noramco”) has filed a motion for judgment on the pleadings under Federal Rule of Civil Procedure 12(c). Noramco argues that it is entitled to judgment as a matter of law on its breach of contract claim against defendant Dishman USA, Inc. (“Dishman”), and on Dishman’s affirmative defenses. Dkt. No. 38. For the reasons set forth below, Noramco’s motion is GRANTED IN PART and DENIED IN PART. I. Background This case involves a contract dispute regarding a supply agreement (the “Agreement”) between Noramco and Dishman.1 Noramco, a manufacturer of active pharmaceutical ingredients (“APIs”), entered into the Agreement with Dishman, in which Dishman agreed to supply Noramco with olivetol, an ingredient used in the production of Noramco’s APIs. The Agreement provided that Dishman would produce the olivetol and supply it to Noramco at Dishman’s facility in Lodariyal, India. The Agreement further provided that the olivetol that Noramco supplied would comply with “current good manufacturing practices” (“cGMP” or “GMP”) as required by

1 The facts in this section are recited as alleged in Noramco’s Second Amended Complaint, Dkt. No. 35. standards promulgated by the U.S. Food and Drug Administration and the European Union. Dkt. No. 35 at ¶¶ 10–11. In February 2020, while Dishman was manufacturing the olivetol to be supplied under the Agreement, the Swiss Agency for Therapeutic Products (“Swissmedic”) and the European

Directorate for the Quality of Medicines and HealthCare (“EDQM”) inspected Dishman’s facility in Lodariyal.2 Following its investigation, Swissmedic issued a report indicating that it found several “major” deficiencies at the facility, one of which was “critical.” Id. at ¶ 48. The report added that Dishman’s “approach on Materials management . . . was considered as not in compliance with EU GMP.” Id. In March 2020, Dishman manufactured six batches of olivetol. On or about March 24, 2020, the batches of olivetol were shipped from Dishman to Noramco. Dishman did not inform Noramco at that time of the Swissmedic and EDQM regulatory inspection of the Dishman facility that had occurred prior to the shipment of the olivetol to Noramco. In April 2020, after learning of the Swissmedic and EDQM inspection, Noramco notified

Dishman of its “concerns about the inspection and potential rejection of the [olivetol].” Id. at ¶¶ 41–42. The two parties then conferred for several months regarding the status of the olivetol. See, e.g., id. at ¶¶ 43–45, 49–54, 65–77. On or about August 11, 2020, Noramco requested that the olivetol be returned to Dishman’s facility, and on August 19, 2020, Noramco notified Dishman in writing that the olivetol Dishman supplied to Noramco did not comply with the Agreement. Id. at ¶¶ 90–91.

2 Noramco alleges that Swissmedic is the “applicable Swiss surveillance authority for GMP compliance.” Dkt. No. 39 at ¶ 15. Noramco’s complaint alleges that following Noramco’s rejection of the olivetol, Dishman agreed to return the olivetol and to issue a full refund for the material. Dishman disputes that assertion. Id. at ¶¶ 96–97; Dkt. No. 37 at ¶ 97. After Dishman failed to take the olivetol back and issue a refund, Noramco brought this lawsuit against Dishman in December 2021.

Since filing its original complaint, Noramco has amended its complaint on two occasions. The operative pleading for purposes of the present motion is Noramco’s Second Amended Complaint, Dkt. No. 35. Dishman filed an Answer to that complaint, Dkt. No. 37, and Noramco subsequently filed this motion for judgment on the pleadings, Dkt. No. 38. On July 19, 2022, I held oral argument on Noramco’s motion. II. Legal Standard Under Federal Rule of Civil Procedure 12(c), “[a]fter the pleadings are closed—but early enough not to delay trial—a party may move for judgment on the pleadings.” A Rule 12(c) motion “will not be granted unless the movant clearly establishes that no material issue of fact remains to be resolved and that [it] is entitled to judgment as a matter of law.” Jablonski v. Pan Am. World

Airways, Inc., 863 F.2d 289, 290 (3d Cir. 1988) (internal quotation marks and citation omitted). The standard that applies to a Rule 12(b)(6) motion to dismiss for failure to state a claim also applies to motions brought under Rule 12(c); that is, in the common situation in which the defendant moves to dismiss the complaint, the court “must accept the truth of all factual allegations in the complaint and must draw all reasonable inferences in favor of the non-movant.” Revell v. Port Auth. of New York, New Jersey, 598 F.3d 128, 134 (3d Cir. 2010). In the less common situation in which the plaintiff moves for judgment on the pleadings, the court must accept as true the factual allegations in the defendant’s answer and construe the factual allegations in the light most favorable to the defendant. 3 United States v. Blumenthal, 315 F.2d 351, 352 (3d Cir. 1963); Fanatics Retail Grp. (Dreams), LLC v. Truax, No. 20-cv-0794, 2020 WL 7042873, at *2 (D. Del. Dec. 1, 2020). More generally, “[t]he purpose of judgment on the pleadings is to dispose of claims where the material facts are undisputed and judgment can be entered on the competing pleadings

and exhibits thereto, and documents incorporated by reference.” Venetec Int’l, Inc. v. Nexus Med., LLC, 541 F. Supp. 2d 612, 617 (D. Del. 2008). III. Discussion A. Breach of Contract Noramco’s principal argument in support of its motion is that Dishman’s Answer “simply does not deny any essential allegation raised by Noramco.” Dkt. No. 39 at 6. Specifically, Noramco argues that Dishman’s statements in its Answer that certain documents speak for themselves amount to admissions of the corresponding allegations in the complaint. See id. at 6– 7. Dishman responds by arguing that those statements do not constitute admissions and that there are substantial factual disputes to be resolved in this case.

Two examples of the allegations in Noramco’s Second Amended Complaint and Dishman’s responses in its Answer provide helpful context for assessing Noramco’s argument. First, paragraph 56 of the Second Amended Complaint alleges that “[a]s a result of the EDQM/Swissmedic inspection Dishman was prohibited from distributing the [olivetol].” Dkt. No. 35 at ¶ 56. In its Answer, Dishman responded that the allegation was “[d]enied as to any legal

3 Noramco states that in this Rule 12(c) proceeding the court must accept all allegations of Noramco’s complaint as true. Dkt. No. 41 at 6. That would be true if it were Dishman, the defendant, that had moved for judgment on the pleadings, but it is not true when it is Noramco, the plaintiff that has sought relief under Rule 12(c). When a plaintiff seeks judgment on the pleadings, the plaintiff is obviously not entitled to have the allegations in its complaint treated as true. conclusions” and “[a]s to factual allegations, the document [the Swissmedic report] speaks for itself.” Dkt. No. 37 at ¶ 56.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Revell v. Port Authority of New York & New Jersey
598 F.3d 128 (Third Circuit, 2010)
Symbol Technologies, Inc. v. Aruba Networks, Inc.
609 F. Supp. 2d 353 (D. Delaware, 2009)
Venetec International, Inc. v. Nexus Medical, LLC
541 F. Supp. 2d 612 (D. Delaware, 2008)
Fesnak & Associates, LLP v. U.S. Bank National Ass'n
722 F. Supp. 2d 496 (D. Delaware, 2010)
Neo Gen Screening, Inc. v. Telechem International, Inc.
69 F. App'x 550 (Third Circuit, 2003)
Nakahara v. NS 1991 American Trust
718 A.2d 518 (Court of Chancery of Delaware, 1998)

Cite This Page — Counsel Stack

Bluebook (online)
Noramco LLC v. Dishman USA, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/noramco-llc-v-dishman-usa-inc-ded-2022.